Overview of chemotherapy for pancreatic cancerARBUCK, S. G.International journal of pancreatology. 1990, Vol 7, Num 1-3, pp 209-222, issn 0169-4197, 14 p.Conference Paper

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trialsJOHNSON, J. I; DECKER, S; SAUSVILLE, E. A et al.British journal of cancer. 2001, Vol 84, Num 10, pp 1424-1431, issn 0007-0920Article

Paclitaxel : Current developmental approaches of the National Cancer InstituteARBUCK, S. G.Seminars in oncology. 1995, Vol 22, Num 6, pp 55-63, issn 0093-7754, SUP15Article

New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1.1)EISENHAUER, E. A; THERASSE, P; RUBINSTEIN, L et al.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 228-247, issn 0959-8049, 20 p.Article

Unusual gastrointestinal complications of interleukin-2 therapyRAHMAN, R; BERNSTEIN, Z; VAICKUS, L et al.Journal of immunotherapy. 1991, Vol 10, Num 3, pp 221-225, issn 1053-8550, 5 p.Article

An overview of topoisomerase I-targeting agentsARBUCK, S. G; TAKIMOTO, C. H.Seminars in hematology. 1998, Vol 35, Num 3, pp 3-12, issn 0037-1963, SUP4Article

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemiaVEY, N; KANTARJIAN, H; ESTEY, E et al.Annals of oncology. 1999, Vol 10, Num 5, pp 577-583, issn 0923-7534Article

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patientsDAHUT, W; HAROLD, N; LIEBERMAN, R et al.Journal of clinical oncology. 1996, Vol 14, Num 4, pp 1236-1244, issn 0732-183XArticle

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemiaBERAN, M; KANTARJIAN, H; KEATING, M et al.Blood. 1996, Vol 88, Num 7, pp 2473-2479, issn 0006-4971Article

Primary therapy of multiple myeloma with paclitaxel (Taxol)DIMOPOULOS, M. A; ARBUCK, S; HUBER, M et al.Annals of oncology. 1994, Vol 5, Num 8, pp 757-759, issn 0923-7534Article

Free and liposomal doxorubicin treatment of intraperitoneal colon 26 tumor: therapeutic and pharmacologic studiesMAYHEW, E; CIMINO, M; KLEMPERER, J et al.Selective cancer therapeutics. 1990, Vol 6, Num 4, pp 193-209, issn 1043-0733, 17 p.Article

Phase 1 clinical trial of cis-dichloro-trans-dihydro-bis isopropylamine platinum (IV) (CHIP) = Essai clinique phase I du cis-dichloro-trans-dihydroxy-bis isopropylamine platine (CHIP) par voie intraveineuseCREAVEN, P. J; MADAJEWICZ, S; PENDYALA, L et al.Cancer treatment reports. 1983, Vol 67, Num 9, pp 795-800, issn 0361-5960Article

Topotecan treatment of adults with primary malignant gliomaFRIEDMAN, H. S; KERBY, T; FIELDS, S et al.Cancer. 1999, Vol 85, Num 5, pp 1160-1165, issn 0008-543XArticle

Paclitaxel as second and subsequent therapy for metastatic breast cancer : activity independent of prior anthracycline responseSEIDMAN, A. D; REICHMAN, B. S; LEPORE, J et al.Journal of clinical oncology. 1995, Vol 13, Num 5, pp 1152-1159, issn 0732-183XArticle

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancerREICHMAN, B. S; SEIDMAN, A. D; YAO, T. J et al.Journal of clinical oncology. 1993, Vol 11, Num 10, pp 1943-1951, issn 0732-183XArticle

Preliminary experience with paclitaxel (TAXOL®) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancerSEIDMAN, A. D; NORTON, L; CURRIE, V et al.Seminars in oncology. 1993, Vol 20, Num 4, pp 40-45, issn 0093-7754, SUP3Conference Paper

Current dosage and schedule issues in the development of paclitaxel (TAXOL®)ARBUCK, S. G; CANETTA, R; ONETTO, N et al.Seminars in oncology. 1993, Vol 20, Num 4, pp 31-39, issn 0093-7754, SUP3Conference Paper

Interspecies differences in in vitro etoposide plasma protein bindingFLEMING, R. A; ARBUCK, S. G; STEWART, C. F et al.Biochemical pharmacology. 1991, Vol 42, Num 11, pp 2246-2249, issn 0006-2952Article

A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinomaARBUCK, S. G; SILK, Y; DOUGLASS, H. O et al.Cancer. 1990, Vol 65, Num 11, pp 2442-2445, issn 0008-543X, 4 p.Article

Factors affecting in vitro protein binding of etoposide in humansFLEMING, R. A; EVANS, W. E; ARBUCK, S. G et al.Journal of pharmaceutical sciences. 1992, Vol 81, Num 3, pp 259-264, issn 0022-3549Article

Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patientsSTEWART, C. F; FLEMING, R. A; ARBUCK, S. G et al.Cancer research (Baltimore). 1990, Vol 50, Num 21, pp 6854-6856, issn 0008-5472, 3 p.Article

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas : results of a phase II trialDECAPRIO, J. A; MAYER, R. J; GONIN, R et al.Journal of clinical oncology. 1991, Vol 9, Num 12, pp 2128-2133, issn 0732-183XArticle

Accelerated titration designs for phase I clinical trials in oncologySIMON, R; FREIDLIN, B; RUBINSTEIN, L et al.Journal of the National Cancer Institute. 1997, Vol 89, Num 15, pp 1138-1147, issn 0027-8874Article

Paclitaxel (taxol) in breast cancerARBUCK, S. G; DORR, A; FRIEDMAN, M. A et al.Hematology/oncology clinics of North America. 1994, Vol 8, Num 1, pp 121-140, issn 0889-8588Article

Page / 3